The Multispecialty Toxin: A Literature Review of Botulinum Toxin

Karen Bach, BS*
Richard Simman, MD, FACS,
FACCWS*†

Background: Botulinum toxin (BoNT) is a potent biological exotoxin produced from Clostridium botulinum. Although it was first used therapeutically to treat strabismus, its clinical role has since expanded rapidly over the years to include treatment of a variety of head and neck, gastrointestinal, urogenital, musculoskeletal, neurological, dermatological, and cosmetic disorders. The main purpose of this review is to provide a brief updated overview of the history, mechanism of action, and clinical applications of BoNT therapy across multiple medical specialties, including the most common adverse effects and recommended Botox dosages.

Methods: A literature review was conducted in the PubMed database limited to English language articles. Specific search terms related to botulinum toxin in combination with various subspecialty fields were used, and relevant articles were identified and analyzed. The reference section for each article was also searched to find additional articles.

Results: BoNT is a powerful therapeutic tool and has a vast array of clinical uses in many specialties, including ophthalmology, neurology, plastic surgery, dermatology, orthopedic, gastrointestinal, gynecology, urology, and rheumatology. Due to its chemodenervation effects at the presynaptic nerve terminal, it is useful in treatments of disorders characterized by abnormal inappropriate muscle contractions.

Conclusions: BoNT has many clinical applications in several medical specialties. Future studies should focus on any additional indications of BoNT therapy as they arise and on any novel product developments. (Plast Reconstr Surg Glob Open 2022;10:e4228; doi: 10.1097/GOX.0000000000004228; Published online 6 April 2022.)

INTRODUCTION

Botulinum toxin (BoNT) is a neurotoxin produced by the Gram-positive, rod-shaped, spore-forming anaerobic bacterium Clostridium botulinum. Although there are seven major serotypes of Botulinum Neurotoxin (BoNT/A-G), only type A and B are used clinically.1 For the purpose of this article, we will refer to this agent as BoNT, and the distinction of Botox and Botox Cosmetic will be used when referring to Food and Drug Administration (FDA)-approved dosages. This literature review primarily serves to provide a historical review of the toxin, assess its mechanism of action, and highlight the many clinical applications of BoNT therapy in an organized, specialty-based manner. Secondary goals aim to cover the most common side effects and toxicity, including their management options, and the recommended Botox dosage relative to their FDA-approved clinical application. Some of the conditions mentioned may be treated by multiple specialties.

METHODS

A literature review was conducted in the PubMed database limited to English language articles published using the terms: “Botulinum Toxin,” “Botulinum Neurotoxin,” “Botulinum Toxin A,” “Botox” in various combinations with “Ophthalmology,” “Neurology,” “Plastic Surgery,” “Dermatology,” “Gastrointestinal,” “Urology,” “Gynecology,” “Rheumatology,” “Orthopedics,” “clinical applications,” “dose,” and “complications.” Articles describing the use of botulinum toxin were selected, reviewed, and summarized in this article. References from each article were also reviewed for additional relevant articles.

Historical Review

Historically, the idea of using BoNT therapeutically originated from Justinus Kerner in the early 1800s. He referred to the toxin as “sausage poison” after noting its...
effects following ingestion of spoiled smoked blood sausages. In 1870, John Muller coined the term “botulism” (the Latin root *botulus* means “sausage”) and in 1895, van Ermengem isolated the bacterium for the first time.2,3 The discovery of the bacterium and toxin led to the investigation of its use as a treatment for strabismus.3,4 Finally, in 1989, it was FDA approved as a therapy for strabismus, blepharospasm, and hemifacial spasm.5,6 In 2000, it was FDA approved for the treatment of cervical dystonia.7,8 Since then, it has been widely accepted and utilized for both on- and off-label by multiple medical specialties for a variety of conditions (Fig. 1).

**Mechanism of Action**

BoNT is synthesized as an inactive 150-kDa single chain polypeptide, which undergoes cleavage, and thus activation, by trypsin or bacterial enzymes into a 100 kDa heavy chain and 50 kDa light chain.9 BoNT selectively and reversibly binds in the presynaptic terminal of the neuromuscular junction to specific membrane protein complexes called SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) to prevent the release of acetylcholine.10 BoNT type A and E cleave the SNARE component SNAP-25 (synaptosomal associated protein),11,12 while type C cleaves both SNAP-25 and syntaxin.14 Type B, D, and F cleave the SNARE component synaptobrevin (vesicle-associated membrane protein or VAMP).13 Without the presynaptic release of acetylcholine, muscle contraction cannot occur, leading to its many beneficial uses in disorders with abnormal, excessive, or inappropriate muscle contractions.

**Commercially Available Formulations of BoNT**

Several FDA-approved commercial formulations of BoNT (Botox, Dysport, Xeomin, Jeuveau, Myobloc/Neurobloc) are available in the United States. Each product differs in pharmaceutical form, units per vial, molecular weight, expedients used for preparation, onset of action, dosing, storage, and FDA-approved indications. A comparison of these properties is provided in Table 1. Due to the distinct pharmacological properties of the formulations, these agents should not be used interchangeably.

**General Complications**

The effects of BoNT are temporary, taking effect within 24–72 hours and lasting anywhere between 3 and 6 months depending on patient-specific factors, indications, and dosage. Dosing can be expressed in terms of international units, where 1 international unit corresponds to the median lethal dose (LD50) to kill 50% of a colony of mice by intraperitoneal injection. The LD50 for humans is approximately 0.8–0.9 µg by inhalation, 30 ng by ingestion, and 0.09–0.15 µg by intravenous route.16 Notably, potency Units (U) are specific to each BoNT preparation and thus, are not interchangeable. Treatment is generally safe and well-tolerated by patients when used appropriately; however, a small subset of patients can experience side effects.17 In most cases, the side effects are localized and self-limiting, such as erythema, edema, bruising, and pain. Systemic complications are rare and severe adverse effects, such as muscle weakness and allergic reactions, tend to be dose-dependent, with the frequency being 23 times higher for therapeutic cases than for cosmetic cases, and can be exacerbated if patients have a history of multiple treatments at the same site within a narrow time interval or concomitant neuromuscular junction disorders.18 As with any procedures that breach the skin barrier, infections are also a possibility. Management of complications tends to focus on symptomatic treatment. Specific complications of BoNT and any antidotal treatment will

**Fig. 1.** Historical timeline of BoNT and its FDA approvals.
| Trade Name (Proprietary Name) | Manufacturer | Serotype | Form | Onset of Action | Length of Therapeutic Effect | Units per Vial | Molecular Weight | Excipients (Per Vial) | Cost Per Unit * | Year of FDA Approval | FDA Approved Indications |
|------------------------------|--------------|----------|------|----------------|-----------------------------|---------------|-----------------|-------------------|----------------|-------------------|-----------------------------|
| Botox (Onabotulinum-toxinA)  | Allergan Inc., Irvine, Calif. | A Powder | 3–5 d (up to 2 wk) | 3–6 mo | 50 or 100 | 900 kDa | HSA (0.5 mg) NaCl (0.9 mg) | Generally most expensive. Ranges from $10–20 per unit in the United States. |
| Dysport (Abobotulinum-toxinA) | Ipsen Limited, Berkshire (UK) | A Powder | Within 24 h | 3–6 mo | 300 or 500 | 500–900 kDa | HSA (0.125 mg) Lactose (2.5 mg) | Generally least expensive. Ranges from $4–8 per unit in the United States. |
| Xeomin (Incobotulinum-toxinA) | Merz Pharmaceuticals GmbH, Frankfurt am Main (Germany) | A Powder | 5–7 d | 3–6 mo | 100 | 150 kDa | HSA (1.0 mg) Sucrose (5 mg) | Slightly less than Botox. Ranges from $8–18 per unit in the United States. |
| Jeuveau (Prabotulinum-toxinB) | Daewoong Pharmaceuticals (South Korea) | A Powder | 3–5 d | 3–6 mo | 50 or 100 | 900 kDa | HSA (0.5 mg) NaCl (0.9 mg) | Same or slightly less than Botox. Ranges from $8–16 per unit in the United States. |
| Myobloc/Neurobloc (Rimabotulinum-toxinB) | Solstice Neurosciences Inc., South San Francisco, CA, (USA) | B Solution | 3–5 d (up to 2 wk) | 3–6 mo | 2500, 5000, or 10,000 | 700 kDa | HSA (0.5 mg) NaCl (5.84 mg) Sodium succinate (1.621 mg) | Variable. |

Of note, Myobloc is the brand name in the United States, Canada, and Korea, whereas Neurobloc is the brand name in the European Union, Norway, and Iceland. Dysport has the fastest time to onset of action, and in general, all BoNT have approximately the same length of therapeutic effect. The average cost of BoNT injections vary depending on severity of the condition, amount of product used, expertise and qualifications of injector, and the geographic office location. Thus, trends on the costs of BoNT have been identified, with Botox typically being the most expensive per unit for treatment of common fine lines and wrinkles, whereas Dysport is the cheapest neuromodulator but more units are typically required to have the same effect.

HSA, human serum albumin; NaCl, sodium chloride.
be further discussed in the sections below according to their use indications.

RESULTS AND DISCUSSION

A detailed description of all the conditions for which BoNT has been shown to be effective in treating is beyond the extent of this article. Only conditions for which BoNT is commonly used will be discussed (Table 2). In addition to indication-specific dosages and administration recommendations of Botox for FDA-approved conditions, the most common adverse reactions will also be discussed (Table 3).

Ophthalmology

As previously mentioned, the therapeutic potential of BoNT was first recognized in 1981 by Scott following their studies of injecting the toxin into ocular muscles to treat strabismus. In 1989, the FDA approved this agent for the treatment of strabismus, blepharospasms, and hemifacial spasm in patients aged younger than 12 years. The current recommended Botulinum dose for strabismus is based on the prism diopter correction or prior treatment response. For blepharospasm, 1.25–2.5 U is recommended for each of the approved three sites per affected eye. The role of BoNT therapy in ophthalmology has since expanded to treat several other conditions, including eyelid retraction due to thyroid disease, apraxia of lid opening, entropion, exposure keratopathy, lacrimal hypersecretion, and chronic dry eyes.

Complications with BoNT use in ophthalmology arise as a result of toxin diffusion or inadvertent placement into the adjacent muscles. Ptosis of the eyelid is the most common complication of BoNT treatment of strabismus and blepharospasms. Although this effect is almost always temporary and self-resolving, apraclonidine 0.5% (Iopidine) or phenylepherine hydrochloride 2.5% (Neosynephrine) ophthalmic solution may be used. These eye drops are adrenergic agonists that help contract the dilator pupillae and improve pupil response. Other reactions include dysphagia, upper respiratory infection, increased cough, and rhinitis. For the treatment of chronic migraine, adverse reactions of bruising, pain, ptosis, and diplopia have been reported.

Neurology

BoNT has many neurological applications in the management of movement disorders and painful conditions. In 2000, the FDA approved its use for the treatment of cervical dystonia in patients 16 and older. The recommended Botox dose for cervical dystonia is dependent on the patient’s presentation, including the head and neck position, pain, and degree of muscle contraction. It is advised to use a lower dose initially if there has been no prior treatment and adjust the dose accordingly based on response. Other movement disorders treated with BoNT besides dystonia include hemifacial spasm, tremor, tics, bruxism, myokymia, neuromyotonia, palatal myoclonus, and spasticity, in addition to synkinesis. Synkinesis refers to abnormal involuntary muscle contraction that occur with voluntary contraction of other muscle groups and in rare cases, such as oculonasal synkinesis, Botox may provide a nonsurgical treatment option to address the paroxysmal contraction. Botox is FDA approved for the treatment of spasticity in both adult and pediatric populations. The recommended dose for spasticity is divided among affected muscles and is as follows: adult upper limb (max 400 U), adult lower limb (300–400 U), pediatric upper limb (3–6 U/kg with a max of 200 U), and pediatric lower limb (4–8 U/kg with a max of 300 U). BoNT therapy has also been proven effective in treating debilitating conditions such as tension headaches, migraines, myofascial pain, temporomandibular joint syndrome, and trigeminal neuralgia. The FDA-approved BoNT in 2010 for the prevention of headaches in adults suffering from chronic migraines who have 15 or more headache days each month, with each episode lasting four hours or more a day. The recommended total Botox dose for chronic migraines is 155 U, with 5 U (0.1 mL) injections per site divided across seven head or neck muscles. The mechanism behind its therapeutic effects relates to the blockade of pain neurotransmission. BoNT has also shown beneficial in treating brachial plexus birth injuries (BPBIs). Administration of the toxin into muscles, such as the pectoralis major, latissimus dorsi, subscapularis, and teres major, help reduce muscle imbalances and excessive inappropriate contractures in brachial plexus birth injuries.

The side effect profile of BoNT use in neurology is generally benign and well-tolerated. For the treatment of cervical dystonia, the most common reported effect is resistance to therapy, with an incidence as high as 6.5%. Other reactions include dysphagia, upper respiratory infection, increased cough, and rhinitis. For the treatment of chronic migraine, adverse reactions of bruising, pain, ptosis, and diplopia have been reported.

Plastic Surgery and Dermatology

In 2002, BoNT was approved by the FDA for cosmetic use to improve the appearance of vertical eye furrows (glabellar lines) when injected into the corrugator or procerus muscles. Injections into the lateral orbicularis oculi can help eliminate lateral canthal wrinkles (crow’s feet) and was granted approval in 2013. Injection into the frontalis muscle targets the horizontal forehead lines while injection into the platysma muscle can improve the appearance of age-related platysma muscle bands. Botox Cosmetic injections are FDA approved only for the glabellar lines, lateral canthal lines, and forehead lines. Wrinkles are caused by dermal atrophy that occurs with aging and repeated contractions of the underlying muscles. When BoNT is injected into these muscles, it causes relaxation of the muscle and improve appearance of overlying lines. The recommended dose for glabellar lines is 4 U (0.1 mL) into each of the five sites, 4 U (0.1 mL) into each of the three sites per side for lateral canthal lines, and 4...
| Specialty                        | FDA-approved Use (Indication-specific Recommended Dosage)                                                                 | Off-label Use                                                                 |
|---------------------------------|---------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Ophthalmology                   | • Strabismus* (variable)                                                                                                  | • Eyelid retraction due to thyroid disease                                    |
|                                 | • Blepharospasm (1.25–2.5 U into each of the three sites per affected eye)                                                 | • Apraxia of lid opening                                                     |
|                                 | • Hemifacial spasm*                                                                                                       | • Entropion                                                                   |
| Neurology                       | • Cervical dystonia (variable)                                                                                             | • Exposure keratopathy                                                        |
|                                 | • Spasticity*                                                                                                              | • Lacrimal hypersecretion                                                     |
|                                 | | Adult upper limb spasticity (400 U total)                                                                               | • Chronic dry eyes                                                            |
|                                 | | Adult lower limb spasticity (300–400 U total)                                                                             | • Pain relief following acute angle closure glaucoma                          |
|                                 | | Pediatric upper limb spasticity (3–6 U/kg; 200 U total)                                                                   | • Other types of dystonia (laryngeal, limb, oromandibular, orolingual, truncal) |
|                                 | | Pediatric lower limb spasticity (4 – 8 U/kg; 300 U total)                                                                   | • Hemifacial spasm*                                                           |
|                                 | | Chronic migraines (5 U (0.1 mL) injections per site divided across seven head or neck muscles; total 155 U)            | • Tremor                                                                      |
|                                 | • Movement disorders:                                                                                                      | • Bruxism*                                                                    |
|                                 | | • Other types of dystonia (laryngeal, limb, oromandibular, orolingual, truncal)                                             | • Myokymia and synkinesis (ie, oculonasal synkinesis)                        |
|                                 | | • Hemifacial spasm*                                                                                                       | • Palatal myoclonus                                                           |
|                                 | | • Tremor                                                                                                                  | **Painful disorders:**                                                       |
|                                 | | • Tics                                                                                                                     | | Tension headaches                                                            |
|                                 | | • Bruxism*                                                                                                                | | Myofascial pain syndrome                                                     |
|                                 | | • Myokymia and synkinesis (ie, oculonasal synkinesis)                                                                     | | Temporomandibular joint (TMJ) disorders* trigeminal Neuralgia                |
|                                 | • Cosmetic use:                                                                                                            | | Brachial plexus injury*                                                      |
|                                 | | • Eyebrow depression                                                                                                      | **Other indications:**                                                       |
|                                 | | • Horizontal nasal bridge lines                                                                                        | | Bruxism*                                                                     |
|                                 | | • Horizontal forehead lines                                                                                               | | Masseter hypertrophy                                                         |
|                                 | | • Vertical lip lines                                                                                                      | | TMJ dysfunction*                                                             |
|                                 | | • Proxis of lateral commissure                                                                                             | | Hyperhidrosis in other regions, such as the palms and soles                 |
|                                 | | • Platysmal neck bands                                                                                                    | | Hidradenitis suppurativa                                                     |
|                                 | | • Gummy smile                                                                                                             | | Frey’s syndrome                                                              |
|                                 | | • Peau d’orange chin                                                                                                      | | Congenital talipes equinovarus                                               |
|                                 | Plastic surgery and dermatology                                                                                           | | Idiopathic toe walking                                                       |
|                                 | • Glabellar lines (4 U (0.1 mL) into each of the five sites; 20 U total)                                                   | | Brachial plexus injury*                                                      |
|                                 | • Lateral canthal lines (4 U (0.1 mL) into each of the three sites per side; 24 U total)                                 | | Sport injuries (ie, lateral epicondylitis/tennis elbow and tendon repair)    |
|                                 | • Forehead lines (4 U (0.1 mL) into each of five forehead lines; 20 U total)                                               | | Posttraumatic elbow stiffness caused by heterotopic ossification            |
|                                 | • Axillary hyperhidrosis (50 U per axilla)                                                                                | | Club foot                                                                    |
| Orthopedics                     | • Spasticity*                                                                                                              | | Piriformis syndrome                                                          |
|                                 | | Adult upper limb spasticity (400 U total)                                                                               | | Esophageal:                                                                  |
|                                 | | Adult lower limb spasticity (300–400 U total)                                                                             | | • Achalasia                                                                  |
|                                 | | Pediatric upper limb spasticity (3–6 U/kg; 200 U total)                                                                   | | • Diffuse esophageal spasms                                                  |
|                                 | | Pediatric lower limb spasticity (4–8 U/kg; 300 U total)                                                                    | **Gastrointestinal:**                                                        |
|                                 | • Gastrointestinal None                                                                                                    | | • Chronic anal fissures                                                      |
|                                 | Urology and gynecology                                                                                                    | | • Rectal fissures or spasms                                                  |
|                                 | • Adult neurogenic detrusor overactivity (~6.7 U (0.1 mL) injections across 30 sites into detrusor; 200 U total)       | | • Anismus                                                                    |
|                                 | • Pediatric neurogenic detrusor Overactivity (0.5 mL injections across 20 sites into detrusor; total dose of 200 U if ≥34 kg and 6 U/kg if <34 kg) | **Biliary:**                                                                  |
|                                 | • Nonneurogenic overactive bladder (5 U (0.5 mL) injections across 20 sites into detrusor; 100 U total)                 | | • Sphincter of oddi dysfunction                                              |
|                                 | Rheumatology None                                                                                                         | **Other indications:**                                                       |
|                                 | Urology and gynecology                                                                                                    | | • Obesity                                                                    |
|                                 | | Adult neurogenic detrusor overactivity (~6.7 U (0.1 mL) injections across 30 sites into detrusor; 200 U total)       | | • Proctalgia fugax                                                           |
|                                 | | Pediatric neurogenic detrusor Overactivity (0.5 mL injections across 20 sites into detrusor; total dose of 200 U if ≥34 kg and 6 U/kg if <34 kg) | | Sterile prostatitis                                                         |
|                                 | | Nonneurogenic overactive bladder (5 U (0.5 mL) injections across 20 sites into detrusor; 100 U total)                 | | Outflow obstruction Symptoms                                                 |

*Denotes conditions that may be treated across multiple specialties. It is important to note that this is not an exhaustive list.
The recommended Botox dose for axillary hyperhidrosis refractory to other topical therapeutics. As of 2004, BoNT is FDA approved for the treatment of severe primary axillary hyperhidrosis refractory to other topical therapeutics. The recommended Botox dose for axillary hyperhidrosis is 50 U per axilla. In a similar manner, BoNT also exerts a therapeutic effect in patients with gustatory sweating of the cheek, also known as Frey’s syndrome. Masseter hypertrophy, although seldom presents a significant issue, may cause pain in some individuals, especially those with TMJ dysfunction or bruxism. BoNT injection into the masseter muscle has reportedly improved pain, and also reduced the size and volume of the muscle. BoNT use for this clinical phenomenon is not FDA-approved yet, and further studies are needed to assess its efficacy and safety.

Complications of cosmetic use of BoNT are typically self-limited and localized to the site of injection. These include the aforementioned pain, erythema, and bruising effects. Diffusion of the toxin during treatment of glabellar lines or peri orbital wrinkles may result in eyelid ptosis, with the most severe cases interfering with vision and requiring treatment with mydriatic agents such as apraclonidine 0.5% (lropine) or phenylephrine hydrochloride 2.5% (Neosynephrine) ophthalmic solution.

Table 3. Summary of Common BoNT Complications and their Management

| Complications | Management of Complications |
|---------------|-----------------------------|
| Local injection reactions | Pain | Ice, EMLA cream, slow injection technique, pinching, use of smaller needles |
| | Swelling and bruising | Ice, arnica, avoidance of blood thinners and NSAIDs |
| | Erythema | Ice |
| | Headache | Analgesics |
| | Infection | Aseptic injection technique, antibiotics (topical or oral) |
| | Ptosis | Injection technique, apraclonidine 0.5% (lropine) or phenylephrine hydrochloride 2.5% (Neosynephrine) ophthalmic solution |
| Distant spread from injection site | Dysphagia or dysarthria | Very rarely requires hospitalizations and tends to self-resolve in a few weeks. Avoid injection into sternocleidomastoid muscle. Symptomatic management and monitoring is key |
| | Unsatisfactory aesthetic results | Self-limiting. Reassure patient |
| | Ophthalmic emergencies (ie, acute angle closure glaucoma, retinal detachments) | Emergency medical management |
| | Respiratory complications (upper respiratory infection, increased cough) | Symptomatic management but emergency medical management if severe |
| | Urinary complications (urinary tract infections, urinary retention) | Screenings for infection before treatment. Prophylactic antibiotic use |
| Systemic involvement | Hypersensitivity reaction | Antihistamine, steroids, epinephrine |
| | Antibodies against botulinum toxin | Patients typically build resistance to treatment. They may require more units for effect or fail to respond to treatment overall. This is non-life-threatening and does not need intervention. May be prevented by avoiding shorter dosing intervals and higher dosages per injection cycle |
| | Systemic botulism | Avoid any medications that may potentiate botulinum toxin effects (ie, aminoglycosides, quinidine, anticholinergics, muscle relaxants). Emergency medical management |

Many of these adverse reactions are self-limiting and can be prevented with proper injection technique. However, it is important to be aware of more serious potential complications to timely manage them.

U (0.1 mL) into each of the five sites for forehead lines, adding up to a final total of 40 U. Fig. 2 provides a brief overview of the frequently injected sites on the face. Other off-label applications in facial rejuvenation include but are not limited to eyebrow depression, nasal bridge lines, perioral rhytids (“smokers lines”), and mesolabial folds (“marionette lines”). Conditions such as migraines, vascular spasms of the hand, and facial paralysis secondary to interventions such as a facelift may also be treated by plastic surgeons. In addition to cosmesis, BoNT has proven therapeutic benefit for the treatment of hyperhidrosis, a condition characterized by excessive sweating in areas such as the axillae, palms, and soles. As of 2004, BoNT is FDA approved for the treatment of severe primary axillary hyperhidrosis refractory to other topical therapeutics. The recommended Botox dose for axillary hyperhidrosis is 50 U per axilla. In a similar manner, BoNT also exerts a therapeutic effect in patients with gustatory sweating of the cheek, also known as Frey’s syndrome. Masseter hypertrophy, although seldom presents a significant issue, may cause pain in some individuals, especially those with TMJ dysfunction or bruxism. BoNT injection into the masseter muscle has reportedly improved pain, and also reduced the size and volume of the muscle. BoNT use for this clinical phenomenon is not FDA-approved yet, and further studies are needed to assess its efficacy and safety.

Complications of cosmetic use of BoNT are typically self-limited and localized to the site of injection. These include the aforementioned pain, erythema, and bruising effects. Diffusion of the toxin during treatment of glabellar lines or peri orbital wrinkles may result in eyelid ptosis, with the most severe cases interfering with vision and requiring treatment with mydriatic agents such as apraclonidine 0.5% (lropine) or phenylephrine hydrochloride 2.5% (Neosynephrine) ophthalmic drops. Other adverse reactions associated with Botox treatment of axillary hyperhidrosis include injection site pain and ecchymosis, nonaxillary sweating, pharyngitis, and flu syndrome.

Orthopedic Surgery

A broad range of clinical disorders in orthopedics may be addressed with BoNT therapy. However, many have underlying pathophysiology similar to that of muscle overactivity and/or spasticity and thus, may also be considered as neurological in nature. The first report of BoNT use in orthopedics was published in 1993 and it described the use of Botox injection to treat spasticity in children with cerebral palsy. Spasticity related to other etiologies, such as multiple sclerosis, head injury, or spinal injury, may also be treated with BoNT injection. FDA approval and dosage recommendations for spasticity have already been discussed in the neurology section above. BoNT has also been reported to be useful in the treatment of piriiformis syndrome, brachial plexus palsy, congenital talipes equinovarus, idiopathic toe walking, and sports-related or posttraumatic injuries. It is important to be cognizant of toxin diffusion into surrounding tissues leading to weakness or paralysis of unwanted musculature. Major serious adverse events are of low incidence, but several accounts of incontinence and respiratory complications...
have been reported in children with cerebral palsy treated with BoNT. The other mentioned BoNT applications are novel and limited in data availability. Subsequent studies are needed to evaluate the long-term complications, if any, of BoNT use in orthopedics.

Gastrointestinal
BoNT has proven to be effective in the management of several gastrointestinal conditions, in particular, those characterized by spasticity of the smooth muscle. Injection into the lower esophageal sphincter has demonstrated impressive results in patients with achalasia and provided a useful alternative treatment in patients who are not candidates for invasive procedures. The use of BoNT in treating anal fissures has also been extensively studied and injection into the anal sphincter has been shown to improve the resolution of chronic anal fissures. Other conditions treated may include diffuse esophageal spasm, gastroparesis, Sphincter of Oddi dysfunction, anismus, anal fissures, and rectal spasms or Proctalgia fugax. Many trials have attempted to use BoNT injection into the antrum or body of the stomach to slow down gastric emptying for weight loss in patients with morbid obesity; however, the results have not been statistically significant. Although gastroenterologists routinely use BoNT, the FDA has not yet approved its use for any gastrointestinal indications.

Injections of BoNT into the esophagus for relief of symptoms in achalasia and other spastic esophageal motility disorders have been associated with mild side effects related to the injection itself or from decreased lower esophageal pressure. However, a few rare complications of acute mediastinitis and acute urinary retention have been reported. There has been one reported case of systemic botulism toxicity secondary to BoNT treatment for gastroparesis. However, it should be noted that the patient had a type of muscular dystrophy known as Emery-Dreifuss and in general, BoNT injection is contraindicated in those with existing neuromuscular disorders due to a baseline reduction in acetylcholine responsiveness. Short term incontinence of gas or stool is a self-resolving side effect in the treatment of chronic anal fissure. Overall, the adverse effects are transient and reversible with use of BoNT in the treatment of esophageal, gastroduodenal, anorectal, and biliary disorders.

Urology and Gynecology
BoNT therapy is currently FDA approved for the treatment of neurogenic detrusor overactivity, which results in presentations such as urinary incontinence, overactive bladder syndrome, and non-neurogenic overactive bladder syndrome. For adult detrusor overactivity with an underlying neurologic condition, the recommended Botox dose is approximately 6.7 U (1 mL) injections across 30 sites in the detrusor muscle for a total of 200 U, and 0.5 mL injections across 20 sites in the detrusor muscle (total dose 200 U if ≥34 kg and 6 U/kg if <34 kg) for pediatric detrusor overactivity with an underlying neurologic condition. In contrast, the...
recommended Botox dose for overactive bladder alone without an underlying neurologic condition is 5 U (0.5 mL) injections across 20 sites in the detrusor muscle for a total dose of 100 U.\(^5\) Off-label use of the toxin is also commonly done for a variety of other genitourinary conditions, including detrusor sphincter dyssynergia, prostatic obstruction, painful bladder syndrome, and other pelvic floor disorders like vaginismus and chronic pelvic pain.\(^54-56\)

For treatment of overactive bladder syndrome and detrusor overactivity, the most common adverse effects are urinary tract infection and urinary retention.\(^57\) These complications could possibly be avoided with screenings for acute urinary tract infections before treatment and prophylactic antibiotic use. The reported complications of BoNT injections for gynecologic indications vary from urinary retention to constipation.\(^58\) In general, use of BoNT in the treatment of multiple urological and gynecological disorders appears to be safe and effective.

**Rheumatology**

In recent years, BoNT has garnered increasing interest for its use in Raynaud’s phenomenon, a condition characterized by an exaggerated vasoconstrictive physiological response of the extremities provoked by cold exposure or emotional stress. The first application for this purpose occurred in 2004, which demonstrated improved blood flow. Subsequently, further studies have proved BoNT’s ability to increase blood flow, relieve painful symptoms of vasospasms, and prevent ischemic ulcerations in these patients. The proposed mechanism of action of BoNT efficacy in Raynaud’s revolves around the agent’s ability to inhibit arteriolar vasoconstriction in a dose-dependent manner via cleavage of SNAP-25 in sympathetic neurons, thus blocking the release of norepinephrine.\(^59\) The most common complication reported is a transient intrinsic weakness of the hand.\(^60\)

**CONCLUSIONS**

The clinical applications of BoNT are extensive as it is used across different medical specialties. The prevention of acetylcholine release at cholinergic junctions makes BoNT effective in the treatment and management of numerous conditions characterized by hyperactivity of muscles and glands. It is important to note that this is not an exhaustive review and that many of the conditions described are not mutually exclusive to any one particular specialty. The main purpose of this review is to provide a brief updated overview of the history, mechanism of action, and most common clinical applications of BoNT therapy across multiple medical specialties, including their complications and recommended Botox dosages.

---

**REFERENCES**

1. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. *Eur J Neurol*. 2001;8(Suppl 5):21–29.
2. Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justus Kerner (1786–1862) and the “sausage poison.” *Neurology*. 1999;53:1850–1853.
3. Devriese PP. On the discovery of Clostridium botulinum. *J Hist Neurosci*. 1999;8:43–50.
4. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. *Trans Am Ophthal Soc*. 1981;79:734–770.
5. Wäbbels B, Reichel G, Fulford-Smith A, et al. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. *J Neurol Transm (Vienna)*. 2011;118:233–239.
6. Carruthers J, Stubbs HA. Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion. *Can J Neurol Sci*. 1987;14:42–45.
7. Tsut J, Eisen A, Ma E, et al. A pilot study on the use of botulinum toxin in spasmic torticollicollis. *Can J Neurol Sci*. 1985;12:314–316.
8. Comella CL, Jankovic J, Brin MF. Use of botulinum toxin type A in the treatment of cervical dystonia. *Neurology*. 2000;55(12 Suppl 5):S15–S21.
9. Montecucco C, Chiari G, Rossetto O. The mechanism of action of tetanus and botulinum neurotoxins. *Arch Toxicol Suppl*. 1996;18:342–354.
10. Hay JC. SNARE complex structure and function. *Exp Cell Res*. 2001;271:10–21.
11. Fon EA, Edwards RH. Molecular mechanisms of neurotransmitter release. *Muscle Nerve*. 2001;24:581–601.
12. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. *Nature*. 1993;365:160–163.
13. Adler M, Keller JE, Sheridan RE, et al. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. *Toxicon*. 2001;39:233–243.
14. Eleopra R, Tognoli V, Quattrale R, et al. Different types of botulinum toxin in humans. *Mon Disord*. 2004;19(Suppl 8):583–589.
15. Foran PG, Mohammed N, Lisk GO, et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of excocytosis in central neurons. *J Biol Chem*. 2003;278:1363–1371.
16. Dhaked RK, Singh MK, Singh P, et al. Botulinum toxin: bio-weapon & magic drug. *Indian J Med Res*. 2010;132:489–503.
17. Mahant N, Clouston PD, Lorentz IT. The current use of botulinum toxin in humans. *J Clin Neurosci*. 2000;7:389–394.
18. Coté TR, Mohan AK, Polder JA, et al. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. *J Am Acad Dermatol*. 2005;53:407–415.
19. Borodic G, Johnson E, Goodnough M, et al. Botulinum toxin therapy, immunologic resistance, and problems with available materials. *Neurology*. 1996;46:26–29.
20. BOTOX (onabotulinumtoxinA) [package insert]. Irvine, Calif.: Allergan, Inc; 2021.
21. Carruthers JD, Carruthers A. Botulinum A exotoxin in clinical ophthalmology. *Can J Ophthalmol*. 1996;31:389–400.
22. Dutton JJ, Fowler AM. Botulinum toxin in ophthalmology. *Surv Ophthalmol*. 2007;52:15–31.
23. Burns CL, Gammon JA, Gemmill MC. Ptosis associated with botulinum toxin treatment of strabismus and blepharospasm. *Ophthalmology*. 1986;93:1621–1627.
